rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

PROCEPT BioRobotics Corporation

PRCT · Nasdaq

Health CareMedical DevicesNot moving yetRobotics

PRCT stood above a rising 150-day average in 0 of the last 52 weekly readings. It is 18.0% below that average now. Medical Devices: 27% of its 181 stocks in an uptrend (−7 points in four weeks); Health Care: 26% (−10 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 52
Industry in uptrend
27% -7 in 4 wk
Insider buys, 12 months
$22.0M
Insider sales, 12 months
$1.2M
Officials’ trades on record
0
Institutions holding
243 (+3)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 0 of 52 weeks.

20 Apr – 19 Oct
19%29%40%Apr 26Jun 26Jul 26Sep 26Oct 26

Medical Devices: A minority of its stocks are in an uptrend and the share has been slipping. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$15.8M$0$19.6MNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months4
Sale orders, 12 months12
Buyers · sellers2 · 3
WhoDidSharesTraded
Barry L. TemplinEVP, Chief Technology Officersold373at $20.959 Sep 2026filed 10 Sep 2026
Alaleh NouriEVP, CLO, CORP. SEC.sold297at $20.959 Sep 2026filed 10 Sep 2026
Kevin WatersEVP, CFOsold373at $20.959 Sep 2026filed 10 Sep 2026
Larry L. WoodPresident, CEObought23,900at $20.857 Aug 2026filed 10 Aug 2026
Barry L. TemplinEVP, Chief Technology Officersold358at $28.488 Jun 2026filed 10 Jun 2026
Kevin WatersEVP, CFOsold357at $28.488 Jun 2026filed 10 Jun 2026
Alaleh NouriEVP, CLO, CORP. SEC.sold285at $28.488 Jun 2026filed 10 Jun 2026
Alaleh NouriEVP, CLO, CORP. SEC.sold3,031at $25.8219 Mar 2026filed 19 Mar 2026
Alaleh NouriEVP, CLO, CORP. SEC.sold2,332at $26.1519 Mar 2026filed 19 Mar 2026
Kevin WatersEVP, CFOsold706at $28.1517 Mar 2026filed 19 Mar 2026
Alaleh NouriEVP, CLO, CORP. SEC.sold304at $28.1517 Mar 2026filed 19 Mar 2026
Alaleh NouriEVP, CLO, CORP. SEC.sold3,098at $25.6010 Mar 2026filed 12 Mar 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders243+3 on the quarter
New · exited41 · 38
Reported value$1.1B

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
BlackRock, Inc.added · filed 7 Aug 20264,869,828$110.0M+507,826+11.6%
BNP PARIBAS ASSET MANAGEMENT Holding S.A.reduced · filed 13 Aug 20262,823,849$63.8M-265,529−8.6%
VANGUARD PORTFOLIO MANAGEMENT LLCadded · filed 13 Aug 20262,526,802$57.1M+105,440+4.4%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20262,460,802$55.6M+61,735+2.6%
Chicago Capital, LLCreduced · filed 28 Jul 20262,073,237$46.8M-87,350−4.0%
STATE STREET CORPadded · filed 7 Aug 20261,617,475$36.5M+87,844+5.7%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 20261,484,163$33.5M+120,663+8.8%
FMR LLCreduced · filed 13 Aug 20261,444,878$32.6M-17,026−1.2%
WELLINGTON MANAGEMENT GROUP LLPadded · filed 14 Aug 20261,274,004$28.8M+412,399+47.9%
FEDERATED HERMES, INC.added · filed 12 Aug 20261,253,420$28.3M+1,078,984+618.6%
31 Mar 2023 – 30 Jun 2026
95172248Mar 23Dec 23Dec 24Sep 25Jun 26

News

Everyone who traded it

Michael Mack Company insiderDirector · last 2 Oct 20260 · 0
Alaleh Nouri Company insiderEVP, CLO, CORP. SEC. · last 9 Sep 20260 · 25
Barry L. Templin Company insiderEVP, Chief Technology Officer · last 9 Sep 20260 · 2
Kevin Waters Company insiderEVP, CFO · last 9 Sep 20260 · 22
Pooja Sharma Company insiderChief Strat/Marketing Officer · last 13 Aug 20260 · 0
Larry L. Wood Company insiderPresident, CEO · last 7 Aug 20261 · 0
Amy M. Dodrill Company insiderDirector · last 9 Jun 20260 · 0
Antal Rohit Desai Company insiderDirector · last 9 Jun 20264 · 15
Dan Puckett Company insiderDirector · last 9 Jun 20260 · 0
Elisabeth Sandoval Little Company insiderDirector · last 9 Jun 20260 · 0
Frederic H. Moll Company insiderDirector · last 9 Jun 20262 · 1
Mary Garrett Company insiderDirector · last 9 Jun 20260 · 0

Same industry

RCEL Avita MedicalLeading+100%
HAE HaemoneticsLeading+48%
ATRC AtriCureLeading+47%
HTFL HeartflowLeading+47%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202563.7%
Operating profit marginFY 2025 · to 31 Dec 2025-33.7%
Free cash flow marginFY 2025 · to 31 Dec 2025-18.9%
Return on capital employedFY 2025 · to 31 Dec 2025-23.5%
Debt to equityFY 2025 · to 31 Dec 20250.14×
Research spendFY 2025 · to 31 Dec 202523.1%
Share count trendFY 2025 · to 19 Feb 20260.1%
Cash and equivalentsFY 2025 · to 31 Dec 2025$286.5M
Free cash flowFY 2025 · to 31 Dec 2025−$58.3M

Analyst forecasts

No analyst forecasts yet.